Gsk Plc Adr (GSK)

Gsk Plc Adr 주식(GSK)의 최신 뉴스

Oct 30, 2026

ILMN Q3 Earnings Call Highlights Higher Guidance and Clinical Growth - Zacks Investment Research

Oct 30, 2026

Oct 29, 2026

GSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth? - Zacks Investment Research

Oct 29, 2026

Oct 28, 2026

GSK (GSK) Q3 Earnings and Revenues Beat Estimates - Zacks Investment Research

Oct 28, 2026

Oct 27, 2026

Gilead to Report Q3 Earnings: How Should You Play the Stock Now? - Zacks Investment Research

Oct 27, 2026

Oct 22, 2026

Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Zacks Investment Research

Oct 22, 2026

Oct 21, 2026

Can Expanding Ivonescimab Development Unlock SMMT's Growth Potential? - Zacks Investment Research

Oct 21, 2026

Oct 21, 2026

Analysts Estimate GSK (GSK) to Report a Decline in Earnings: What to Look Out for - Zacks Investment Research

Oct 21, 2026

Oct 20, 2026

Metabolic Dysfunction-Associated Steatohepatitis Clinical Trial and Competitive Landscape Expands as 180+ Companies Target New Treatment Options | DelveInsight - GlobeNewswire Inc.

Oct 20, 2026

Oct 20, 2026

HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China - GlobeNewswire Inc.

Oct 20, 2026

Oct 20, 2026

GSK's New Drugs and Pipeline Hold the Key to Long-Term Growth - Zacks Investment Research

Oct 20, 2026

Oct 19, 2026

Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer - GlobeNewswire Inc.

Oct 19, 2026

Oct 15, 2026

GSK plc (GSK) Stock Climbs 2.40% to $49.02, Positioned Evenly Between Support and Resistance - Earnings Beat Stocks - dars.gov.et

Oct 15, 2026

Oct 15, 2026

GSK plc (GSK) Stock Climbs 2.40% to $49.02, Positioned Evenly Between Support and Resistance - Wave Alternation - https://www.siam.in/

Oct 15, 2026

Oct 15, 2026

Could Investing $5,000 in D-Wave Quantum Stock Today Make You a Millionaire? - The Motley Fool

Oct 15, 2026

Oct 14, 2026

At £17.3550 per ordinary share, dividend reinvestment adds to GSK (GSK) executives’ interests. - Stock Titan

Oct 14, 2026

Oct 14, 2026

Prediction: These 3 Dividend Stocks Will Raise Their Payouts No Matter What the Market Does - The Motley Fool

Oct 14, 2026

Oct 13, 2026

Call options on 1.5M shares feature in a passive Silence Therapeutics (SLN) stake. - Stock Titan

Oct 13, 2026

Oct 13, 2026

MRNA Stock Gains Over $4B in a Week: Time to Buy, Hold or Sell? - Zacks Investment Research

Oct 13, 2026

Oct 13, 2026

Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool

Oct 13, 2026

Oct 13, 2026

Dividend reinvestment brings GSK (NYSE: GSK) CEO Luke Miels 23.331 ordinary shares. - Stock Titan

Oct 13, 2026

Oct 12, 2026

Complicated Urinary Tract Infections Market Set for Expansion by 2036, Supported by Recent Drug Approvals Including GSK/Spero Therapeutics’ UTEBZI and Wockhardt’s ZAYNICH and Emerging Therapies | DelveInsight - GlobeNewswire Inc.

Oct 12, 2026

Sep 12, 2026

SGIOY Stock Price, Quote & News - Syfe

Sep 12, 2026

Sep 30, 2026

Hatteras Venture Partners Names Sir Andrew Witty as Chairman and Ned Sharpless, M.D., as Managing Director of Hatteras Discovery Innovation, Expanding Proven Investment Strategies - GlobeNewswire Inc.

Sep 30, 2026

Sep 29, 2026

GSK vs. SNY: Which Europe-Based Pharma Stock Has More Potential? - Zacks Investment Research

Sep 29, 2026

Sep 27, 2026

HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors - GlobeNewswire Inc.

Sep 27, 2026

Sep 24, 2026

Form 13D/A Opera Limited For: 24 September By Investing.com - Investing.com UK

Sep 24, 2026

Sep 22, 2026

GSK (NYSE: GSK) board members are buying company stock - Stock Titan

Sep 22, 2026

Sep 14, 2026

HSBC sets exchange rates for second interim dividend By Investing.com - Investing.com UK

Sep 14, 2026

Sep 11, 2026

Renalytix rises 7% as UBS holding grows and CEO buys shares - Yahoo Finance UK

Sep 11, 2026

Sep 10, 2026

GSK's Specialty Medicines Drive Growth Amid Looming HIV Patent Cliff - Zacks Investment Research

Sep 10, 2026

Sep 08, 2026

Monoclonal Antibodies Market to Grow at 11.01% CAGR, Reaching USD 791.28 Billion by 2035 – SNS Insider - GlobeNewswire Inc.

Sep 08, 2026

Sep 08, 2026

GSK plc (GSK) stock price, news, quote and history - Yahoo Finance Australia

Sep 08, 2026

Sep 07, 2026

Drug Repurposing Market to Reach USD 50.91 Billion by 2035, Expanding at 3.93% CAGR | SNS Insider - GlobeNewswire Inc.

Sep 07, 2026

Sep 02, 2026

Zacks Investment Research - גלובס

Sep 02, 2026

Sep 01, 2026

GSK Stock Down 14% in Six Months: Time to Buy, Hold or Exit? - TradingView

Sep 01, 2026

Aug 31, 2026

GSK stock holds steady as investors weigh recent earnings and dividend - ad-hoc-news.de

Aug 31, 2026

Aug 30, 2026

BNTX Stock Price, Quote & News - Syfe

Aug 30, 2026

Aug 26, 2026

Measles Kills 2 in Pennsylvania: What Do Prediction Markets Say About the Disease? - sahmcapital.com

Aug 26, 2026

Aug 25, 2026

GSK (GSK) Results Breakdown: The Available Earnings Metric Delivers a Beat in the Latest Session; Post-Earnings: Shares Move Lower 1.20% in Latest Trading - Growth Acceleration Report - careplusvn.com

Aug 25, 2026

Aug 25, 2026

GSK (GSK) Results Breakdown: The Available Earnings Metric Delivers a Beat in the Latest Session; Post-Earnings: Shares Move Lower 1.20% in Latest Trading - Earnings Decline Risk - dars.gov.et

Aug 25, 2026

Aug 25, 2026

GSK (GSK) Results Breakdown: The Available Earnings Metric Delivers a Beat in the Latest Session; Post-Earnings: Shares Move Lower 1.20% in Latest Trading - One-Time Gain Impact - www.dars.gov.et

Aug 25, 2026

Aug 25, 2026

GSK (GSK) Results Breakdown: The Available Earnings Metric Delivers a Beat in the Latest Session; Post-Earnings: Shares Move Lower 1.20% in Latest Trading - EPS Growth Report - https://www.dars.gov.et/

Aug 25, 2026

Aug 24, 2026

Resilient GSK stock holds firm as FDA and Japan clear key drugs - ad-hoc-news.de

Aug 24, 2026

Aug 21, 2026

Resilient GSK stock steadies after recent earnings beat and sector scrutiny - ad-hoc-news.de

Aug 21, 2026

Aug 20, 2026

ETFs Investing in GSK plc Sponsored ADR Stocks - TradingView

Aug 20, 2026

Aug 20, 2026

GSK (GSK) Q2 2026 Earnings: The Bottom-Line Figure Beats Its Comparison on the Day; Price Move: Shares Fall 1.74% on the Day - Profit Cycle Analysis - careplusvn.com

Aug 20, 2026

Aug 20, 2026

GSK (GSK) Q2 2026 Earnings: The Bottom-Line Figure Beats Its Comparison on the Day; Price Move: Shares Fall 1.74% on the Day - Revenue Breakdown Analysis - dars.gov.et

Aug 20, 2026

Aug 20, 2026

GSK (GSK) Q2 2026 Earnings: The Bottom-Line Figure Beats Its Comparison on the Day; Price Move: Shares Fall 1.74% on the Day - Earnings Power Value - dars.gov.et

Aug 20, 2026

Aug 20, 2026

GSK (GSK) Q2 2026 Earnings: The Bottom-Line Figure Beats Its Comparison on the Day; Price Move: Shares Fall 1.74% on the Day - CEO Earnings Statement - https://www.dars.gov.et/

Aug 20, 2026

Aug 19, 2026

GSK (GSK) Latest: Ends Higher by 2.35% at $52.35 at the Close; Market Levels: $49.73 and $54.97 Define the Nearby Reference Levels at the Close - Volume Weighted Price - careplusvn.com

Aug 19, 2026